Veru confirms sabizabulin findings with Phase III study

Miami, USA-based Veru (Nasdaq: VERU) has presented Phase III results on sabizabulin in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) at the International Conference on Emerging Infectious Diseases.

Sabizabulin is an oral, novel microtubule disruptor that has dual antiviral and anti-inflammatory activity. A 9mg dose was compared in the trial to placebo in 204 hospitalized moderate to severe COVID-19 patients who were at high risk for ARDS and death.

"We have scaled up manufacturing to meet the demands of this summer’s COVID-19 surge as well as the seasonal surges that are expected in fall and winter"